Amgen director Omar Ishrak receives stock award

Amgen Inc. director Omar Ishrak reported an acquisition of 85.1685 shares of Amgen common stock on 2026-08-07 as a grant or award, at a stated price of $0.0000 per share.

Rhea-AI Filing Summary

Amgen Inc. director Omar Ishrak reported an acquisition of 85.1685 shares of Amgen common stock on 2026-08-07 as a grant or award, at a stated price of $0.0000 per share. Following this award, he holds 7,485.9046 shares directly. A related footnote states that these holdings include 460 Dividend Equivalents (DEs) credited to unvested Restricted Stock Units under Amgen’s Second Amended and Restated 2009 Equity Incentive Plan, which are paid out in common shares on a one-to-one basis according to the RSU vesting schedule, with any remaining fractional share settled in cash.

Insider Trade Summary

Grant/Award: 85.1685 shares

Grant/Award 1 txn

Insider ISHRAK OMAR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	85.1685	$0.00	$0.00

Holdings After Transaction: Common Stock — 7,485.9046 shares (Direct)

Footnotes (1)

1. F1. These shares include 460 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Key Figures

Shares acquired: 85.1685 shares Holdings after transaction: 7,485.9046 shares Dividend Equivalents: 460 DEs +1 more

4 metrics

Shares acquired 85.1685 shares Grant or award of Amgen common stock on 2026-08-07

Holdings after transaction 7,485.9046 shares Direct ownership of Amgen common stock following the award

Dividend Equivalents 460 DEs DEs credited to unvested RSUs under Amgen’s 2009 Equity Incentive Plan

Reported price per share $0.0000 Price per share for the 85.1685-share grant or award

Key Terms

Dividend Equivalents (DEs), Restricted Stock Units, equity incentive plan, qualifying dividend reinvestment plan

4 terms

Dividend Equivalents (DEs) financial

"These shares include 460 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second"

Restricted Stock Units financial

"DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

equity incentive plan financial

"granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

qualifying dividend reinvestment plan financial

"and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Amgen (AMGN) director Omar Ishrak report on this Form 4?

Omar Ishrak reported a grant or award of 85.1685 shares of Amgen common stock on 2026-08-07. This was filed as an acquisition of non-derivative common stock, not an open-market purchase or sale.

How many Amgen (AMGN) shares does Omar Ishrak hold after this Form 4 transaction?

After the reported award, Omar Ishrak directly holds 7,485.9046 shares of Amgen common stock. This total includes shares associated with Dividend Equivalents linked to his unvested Restricted Stock Units.

What are the Dividend Equivalents (DEs) mentioned in Omar Ishrak’s Amgen (AMGN) Form 4?

The filing states that Ishrak’s holdings include 460 Dividend Equivalents (DEs) granted under Amgen’s 2009 Equity Incentive Plan. DEs are credited to unvested RSUs and are paid out in common shares on a one-to-one basis as the RSUs vest, with cash for any remaining fraction.

Was Omar Ishrak’s Amgen (AMGN) Form 4 transaction part of a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and the transaction is described as a grant or award acquisition. There is no indication that this particular award was executed under a trading plan.

What price per share is reported for Omar Ishrak’s Amgen (AMGN) stock award?

The Form 4 reports a transaction price per share of $0.0000 for the 85.1685 shares acquired. This aligns with the transaction being a grant or award rather than a market purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 08:24 PM Accepted by SEC EDGAR 08/10/2026 - 08:24 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ISHRAK OMAR

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/07/2026		A		85.1685	A	$0	7,485.9046(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 460 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ S. Omar Ishrak	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)